Skip to main content

NovaBay Pharmaceuticals looking to grow its three verticals of eye, skin, and wound care in 2023

--News Direct--

NovaBay Pharmaceuticals CEO Justin Hall joined Steve Darling from Proactive to talk more about the company that has developed scientifically proven eye care, skin care and wound care products. The company's top product is Avenova, which has proven in laboratory testing to have broad antimicrobial properties as it removes foreign material and debris from the skin around the eye, including the eyelid.

Hall telling Proactive the company acquired DermaDoctor, a skincare brand, in 2021. He emphasizes that all their products are doctor-recommended and clinically developed to address specific needs.

NovaBay aims to excel in all three verticals, including wound care, and expects continued growth and success.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/novabay-pharmaceuticals-looking-to-grow-its-three-verticals-of-eye-skin-and-wound-care-in-2023-274486627

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.35
+0.59 (0.26%)
AAPL  273.67
+1.48 (0.54%)
AMD  213.43
+12.37 (6.15%)
BAC  55.27
+1.01 (1.86%)
GOOG  308.61
+4.86 (1.60%)
META  658.77
-5.68 (-0.85%)
MSFT  485.92
+1.94 (0.40%)
NVDA  180.99
+6.85 (3.93%)
ORCL  191.97
+11.94 (6.63%)
TSLA  481.20
-2.17 (-0.45%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.